Atacama Labs Oy
This article was originally published in Start Up
Executive Summary
Atacama Labs aims to create better oral solid-dosage forms using a pneumatic dry granulation process that it claims can granulate virtually any active drug ingredient. To prove the worth of its technology to potential clients, Atacama has applied its method to two drugs that are notoriously difficult to dry-formulate: paracetamol for pain and metformin for diabetes. That mission has been accomplished, and now Atacama is inviting drug companies to send it proprietary compounds that they deem their most difficult to formulate.